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Further investigations are needed to evaluate the prognostic 
value of metformin on kidney cancer patients.
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Introduction
Renal cell carcinoma (RCC) is recognized as the most 
common and lethal cancer of kidney cancer, accounting for 
85% of all kidney cancers [1, 2]. What is more, the increas-
ing incidence of kidney cancer is mostly attributed to the 
widely use of diagnostic imaging and the increasing rates 
of hypertension and obesity [3]. In addition, several stud-
ies have demonstrated that kidney cancer patients with dia-
betes mellitus have poorer survival compared with those 
without diabetes mellitus [4–6]. Another three articles also 
found that diabetes mellitus may be an independent risk 
factor for the survival of kidney cancer patients [7–9].
Metformin, a biguanide, is widely used for the therapy of 
diabetes with sulphonylureas [10]. Except for its use in dia-
betes, accumulating evidence has investigated that it could 
improve the survival of cancer patients including breast 
cancer, colorectal cancer, and prostate cancer patients [11–
13]. However, its effects on the survival of kidney cancer 
remain unclear. The articles reported by Nayan et al. [14, 
15] showed that the use of metformin was not associated 
with the overall survival (OS), cancer-specific survival 
(CSS), and disease-free survival (DFS) of RCC patients. 
However, Keizman et al. [16] found that RCC patients 
treated with metformin have lower risk of mortality than 
those without metformin therapy. In addition, another study 
found that compared to metformin non-users, metformin 
use on RCC patients was in favor of better CSS and DFS 
Abstract 
Purpose The effects of metformin on the prognosis of 
kidney cancer patients with diabetes are in controversial. 
The present study is conducted to classify the association 
of metformin use with the survival of patients with kidney 
cancer.
Methods Electronic databases, namely PubMed and Web 
of Science, were used to search the eligible studies up to 
December, 2016. Pooled hazard ratio (HR) and its corre-
sponding 95% confidence interval (95% CI) were calcu-
lated. It was considered as statistically significant when P 
value was <0.05.
Results Eight cohorts were eligible for the present meta-
analysis, including 254,329 kidney cancer patients. The 
combined HR suggested that the use of metformin could 
improve the overall survival (OS) (HR 0.643, 95% CI 
0.520–0.795, P < 0.001) and cancer-specific survival (CSS) 
(HR 0.618, 95% CI 0.446–0.858, P = 0.004) in kidney 
cancer patients. In subgroup analysis, positive associations 
were found between metformin use and OS/CSS of local-
ized renal cell carcinoma patients (OS: HR 0.634, 95% CI 
0.440–0.913, P = 0.014; CSS: HR 0.476, 95% CI 0.295–
0.768, P = 0.002). Moreover, we also found that the use of 
metformin could reduce the risk of death in kidney cancer 
patients (HR 0.711, 95% CI 0.562–0.899, P = 0.004).
Conclusion Our findings suggest that the use of metformin 
is in favor of the prognosis of patients with kidney cancers. 
 * Yonghua Mi 
 yonghuami@163.com
1 Department of Nephrology, Yongchuan Hospital, Chongqing 
Medical University, Chongqing 402160, China
2 Department of Clinical Laboratory, Yongchuan Hospital, 
Chongqing Medical University, Chongqing 402160, China
 Int Urol Nephrol
1 3
[17]. Thus, the impact of metformin on survival outcomes 
of patients with kidney cancer was in controversial.
To obtain a more comprehensive estimation of the prog-
nostic significance of metformin in RCC patients, we per-
formed the present meta-analysis to explore the effects of 




We performed a comprehensive search of two electronic 
databases, namely PubMed and Web of sciences (up to 
November 2016). The search strategy was based on Mesh 
headings, key words and text words as follows: “met-
formin” combined with “kidney cancer” or “kidney carci-
noma” or “kidney neoplasm” or “renal cancer” or “renal 
carcinoma” or “renal neoplasm” or “renal cell carcinoma”. 
In addition, the references listed in the retrieved studies 
were also reviewed.
Selection of the eligible studies
We firstly comprehensively screened the titles and abstracts 
of the candidate articles. Then, the full text was reviewed 
to exclude the articles which could not be eliminated at the 
initial screening of the titles and abstracts.
The criteria for eligible studies were defined as: (1) arti-
cles published in English; (2) original studies, not review 
or meta-analysis; (3) patients diagnosed as kidney cancer 
patients with diabetes; (4) articles estimating the associa-
tion between metformin use and survival of kidney can-
cer patients; (5) eligible data could be obtained including 
hazard ratio (HR) and 95% confidence interval (95% CI); 
exclusion criteria: (1) letters, reviews, and articles not pub-
lished; (2) articles without the eligible data of either HR or 
95% CI.
Data extraction
If available, the following items were extracted: name of 
first author, country, population, publication date, mean 
or median age, follow-up time (mean or median months), 
total number of patients, amount of male patients, number 
of patients received surgery therapy, counts of metformin 
users and metformin non-users, pathological type of kidney 
cancer (localized RCC or metastatic RCC), HR and 95% 
CI of the patients’ survival outcomes.
Statistical analysis
Pooled HR and its corresponding 95% CI were used to 
evaluate the association of metformin use with OS, PFS, 
DFS, and CSS of kidney cancer. It suggested poor prog-
nosis when HR was larger than 1 and the corresponding 
95% CI did not overlap 1. Q-tests and I-squared test were 
used to assess the statistical heterogeneity of studies. It was 
considered as no obvious heterogeneity when P ≥ 0.05 or 
I2 ≤ 50%. We performed sensitivity analysis by sequen-
tially omitting individual studies when there was statisti-
cally heterogeneity. Publication bias was only performed 
for meta-analysis involving more than five studies via 
Begg’s test and Egger’s test. STATA 11.0 was used to ana-
lyze the results, and it was considered as statistically sig-
nificant when P < 0.05.
Results
Main characteristics of the included studies
Thirty-two articles were identified in our meta-analysis, of 
which 18 articles were eliminated at the initial screening of 
the title and abstract. Finally, eight eligible publications [1, 
14–20] were included after comprehensively reviewing the 
full text. Detailed search strategy is shown in Fig. 1. The 
main characteristics of the eligible studies for metformin 
use on kidney cancer patients are summarized in Tables 1 
and 2. A total of 254,329 patients were included, of which 
male patients accounted for 52.5%. In addition, there were 
four studies on localized RCC [14, 15, 19, 20], two studies 
on metastatic RCC [16, 18] and one study both on localized 
and metastatic RCC [17].
Outcomes of all‑caused mortality
The association of metformin use with OS of kidney can-
cer patients was reported in six articles involving 253,150 
patients [1, 14–16, 18, 19], three localized RCC studies 
(1054 patients) [14, 15, 19] and two metastatic RCC studies 
(4484 patients) [16, 18]. The pooled HR showed that com-
pared to patients without being exposed to metformin, a 
reduced risk of mortality was observed in patients exposed 
to metformin [HR (95% CI) 0.41 (0.38–0.45), P < 0.001]. 
However, there was significant heterogeneity among these 
studies (P < 0.001, I2 = 97.1%). Although we performed 
subgroup analysis, it was difficult to find the source of 
heterogeneity. Then we conducted sensitivity analysis 
and found the source of heterogeneity was from the stud-
ies reported by Nayan et al. [14], Hamieh et al. [18] and 
Tseng et al. [1] which composed of much more patients 
than the rest. The summary HR (95% CI) was changed to 
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0.643 (0.520–0.795) (I2 = 40.6%, Pheterogeneity = 0.168; 
Z = 4.08, P < 0.001, Fig. 2a) after exclusion of the stud-
ies contributed to the heterogeneity. In addition, subgroup 
analyses were used to identify the different influences 
of metformin use on populations from different regions 
of the world and patients with or without metastases. 
We found a significant reduced risk of death in localized 
RCC patients exposed to metformin [HR (95% CI):0.634 
(0.440–0.913), I2 = 0.00%, Pheterogeneity = 0.375; Z = 2.45, 
P = 0.014, Fig. 2b]. The results also showed that the use 
of metformin was in favor of weakening the risk of death 
for North American RCC patients [HR (95% CI) 0.711 
(0.562–0.899), I2 = 0.00%, Pheterogeneity = 0.489; Z = 2.84, 
P = 0.004, Fig. 2c]. Although we observed the same result 
in RCC patients with metastasis, there was significant het-
erogeneity [HR (95% CI) 0.648 (0.449–0.841), I2 = 76.5%, 
Pheterogeneity = 0.039; Z = 3.26, P = 0.001].
Outcomes of kidney cancer‑specific survival
The relationship of metformin use with kidney cancer-
specific mortality was studied in five articles recruiting 
2228 patients [14, 15, 17, 19, 20], four studies [14, 15, 19, 
20] on localized RCC (1838 patients) and one study [17] 
both on localized and metastatic RCC (290 localized RCC 
patients and 100 metastatic patients). Although the pooled 
HR suggested that no association was observed between 
CSS and patients exposed to metformin or not, there was a 
high degree of heterogeneity [HR (95% CI) 0.830 (0.658–
0.1.048), I2 = 57.8%, Pheterogeneity = 0.037; Z = 1.57, 
P = 0.117]. In the sensitivity analysis, we found the study 
reported by Nayan et al. [14] contributed to the heterogene-
ity. There was no significant heterogeneity after the omis-
sion of the study published by Nanyan et al. [14] And the 
risk of kidney cancer specific due to kidney carcinoma was 
decreased in patients treated with metformin in compari-
son with the patients without use of metformin [HR (95% 
CI) 0.618 (0.446–0.858), I2 = 28.5%, Pheterogeneity = 0.232; 
Z = 2.87, P = 0.004, Fig. 3a]. Moreover, in the subgroup 
analysis, the use of metformin reduced the risk of death 
in patients with localized RCC patients [HR (95% CI) 
0.476 (0.295–0.768), I2 = 12.30%, Pheterogeneity = 0.331; 
Z = 3.04; P = 0.002, Fig. 3b]. No associations were found 
between the use of metformin and the North American 
populations with RCC [HR (95% CI) 0.606 (0.349–1.053), 
I2 = 0.00%, Pheterogeneity = 0.293; Z = 1.78; P = 0.076].
Outcomes of DFS and PFS
In the present study, two articles were on PFS (4844 met-
astatic RCC patients) [16, 18] and four articles were on 
DFS (1515 localized RCC patients) [15, 17, 19, 20]. The 
pooled HRs showed that there was no associations between 
metformin use and PFS/DFS of RCC patients [PFS: 0.919 
(0.791–1.067), I2 = 0.00%, Pheterogeneity = 0.388, Z = 1.11, 
P = 0.266; DFS: I2 = 34.5%, Pheterogeneity = 0.205, 
Z = 1.72; P = 0.086].
Publication bias
The Begg’s test and Egger’s test were used to evaluate the 
publication bias in meta-analysis. The results of Begg’s 
test and Egger’s test revealed no obvious publication bias 
with considering the existence of heterogeneity or not [OS: 
Pbegg’s = 0.548, Pegger’s = 0.097 (with heterogeneity); CSS: 
Pbegg’s = 0.260, Pegger’s = 0.080 (with heterogeneity) CSS: 
Pbegg’s = 0.73, Pegger’s = 0.307 (without heterogeneity)].
Discussion
Key findings
The present meta-analysis is the first to discover the asso-
ciation between metformin and kidney cancer patients. The 
results showed that metformin could improve the OS [HR 
(95% CI) 0.643 (0.520–0.795), P < 0.001] and CSS [HR 
(95% CI) 0.618 (0.446–0.858), P = .0004] of patients with 
kidney cancer. In the subgroup analysis, we also found that 
in kidney cancer patients, metformin users could have bet-
ter prognosis (OS) than metformin non-users. In addition, 
Fig. 1  The procedure of the search strategy
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the subgroup analysis also suggested that compared to 
patients treated without metformin, OS and CSS were 
both improved in localized RCC patients treated with met-
formin, which was not found in metastatic RCC. Neverthe-
less, our current meta-analysis did not show association of 
metformin with the DFS and PFS of kidney cancer.
Comparison with other studies
The results of our meta-analysis on OS and CSS were in 
consistent with the previous studies. It has been reported 
by Tseng et al. [1] that better OS was associated with the 
use of metformin in kidney cancer patients. Moreover, 
Keizman et al. [16] and Psutka et al. [19], respectively, 
found in metastatic and localized RCC that the risk of 
mortality was reduced in cancer patients. Up to data, only 
one study related to localized RCC demonstrated that met-
formin could decrease the risk of kidney cancer-specific 
death in RCC patients [17]. However, another three arti-
cles identified that metformin showed no association with 
the OS of both localized and metastatic RCC patients [14, 
15, 18]. Meanwhile, four researches associated with local-
ized and metastatic RCC suggested that the use of met-
formin had no effects on the CSS of patients with RCC 
[14, 17, 19, 20]. In addition, among five studies on DFS, 
only one study published by Cheng et al. [17] showed 
positive association between metformin use and the DFS 
of localized RCC patients, which was in contrast to our 
findings. Additionally, two studies on PFS found that there 
were no effects of metformin on the PFS of metastatic 
RCC patients [16, 18].
Strengthens and weakness
We are the first to explore the influence of metformin on 
the prognosis of kidney cancer patients with diabetes. 
And in this meta-analysis, localized RCC and metastatic 
RCC are both included. Moreover, we also conducted 
subgroup analysis to identify the different effects of met-
formin on localized and metastatic RCC. However, there 
are limitations in our meta-analysis. The sample size and 
population differ in different articles included in this 
meta-analysis, which may contribute to the heteroge-
neity and affect the outcomes of this meta-analysis. As 
shown in Table 1, the sample size of the article reported 
by Tseng et al. [1] is much larger than other articles and 
the patients included in this study are Asian, which con-
tribute to the heterogeneity of this meta-analysis and play 
a great role in identifying the influences of metformin on 
the prognosis of Asian kidney cancer patients. The sub-
group analysis in Fig. 2c also has shown that only one 
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Asian kidney cancer patients. Therefore, further studies 
are needed to explore the association between metformin 
use and various populations to exclude the heterogene-
ity. And the patients of the eligible studies are mostly 
diagnosed as localized RCC, which makes it difficult to 
investigate the association between the use of metformin 
and outcomes of metastatic RCC patients. In addition, 
the clinical information extracted from the eligible stud-
ies were limited, which makes it difficult to make further 
subgroup analysis to analyzed whether the impacts of 
metformin on kidney cancer patients are related with age, 
sex, and other characteristics.
Conclusion
The current meta-analysis suggests that the use of met-
formin could improve the OS and CSS of kidney can-
cer patients, especially localized RCC patients. How-
ever, due to the limitations of this meta-analysis, further 
Table 2  Survival data on 
prognosis of the included 
studies in this meta-analysis
a Metformin users versus other antidiabetic therapy
b Metformin users versus antidiabetic therapy non-users
Author Survival analysis Univariate HR (95% CI) P value Multivariate HR (95% CI)
Nayan et al. OS, CSS OS: 0.99 (0.78–1.25) OS: 1.09 (0.85–1.40)
CSS: 1.12 (0.80–1.55) CSS: 1.25 (0.88–1.77)
Hamieh et al. OS, PFS OS: 0.771 (0.566–1.049)a 0.098
OS: 1.053 (0.837–1.324)b 0.6606
PFS: 0.905 (0.682–1.199)a 0.4858
PFS: 0.979 (0.806–1.189)b 0.8274
Nayan et al. OS, CSS, DFS OS: 0.86 (0.40–1.85) 0.07
CSS: 0.38 (0.08–1.86) 0.23
DFS: 0.99 (0.36–2.74) 0.98
Keizman et al. OS, PFS OS: 0.42 (0.26–0.69) 0.001
PFS: 0.71 (0.47–1.08) 1
Cheng et al. CSS, DFS CSS: 0.23 (0.09–0.61) 0.0028
DFS: 0.47 (0.27–0.81) 0.0058
Cheng et al. CSS CSS: 0.78 (0.50–1.23) 0.29
Psutka et al. OS, CSS, DFS OS: 0.58 (0.38–0.87) 0.01
CSS: 0.62 (0.32–1.21) 0.16
DFS: 0.87 (0.51–1.48) 0.6
Hakimi et al. CSS, DFS CSS: 0.76 (0.21–2.70) 0.7
DFS: 1.02 (0.59–1.74) 1 DFS: 1.22 (0.66–2.27)
Tseng et al. OS OS: 0.279 (0.254–0.307) <0.0001
Fig. 2  Association between metformin exposure and OS of kidney cancer patients. a All studies with excluding the source of heterogeneity; 
subgroup analysis, b studies related with localized RCC, c studies associated with North American patients
 Int Urol Nephrol
1 3
investigations are needed to be conducted to identify the 
different effects of metformin on patients with localized 
and metastatic RCC.
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